Bmy stock forecast 2025 bMY’s 2025 growth outlook remains

BMY’s 2025 growth outlook remains linked to cell therapy adoption rates, which market models suggest could accelerate topline figures faster than consensus projections. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Bristol-Myers Squibb? Access our full analysis report here, it’s free . Find stocks with ease across diverse datasets and filters Institutional analyst calls for BMY stock forecast 2025 focus on capital allocation discipline, with $4B earmarked for share repurchases, aiding EPS accretion.